These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 18483295)

  • 1. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo.
    Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Payne JE; Jenkins DA; Bonnefous C; Trotter C; Wang Y; Anzola JV; Milkova EL; Hoffman TZ; Dozier SJ; Wiley BM; Saven A; Malecha JW; Davis RL; Muhammad J; Shiau AK; Noble SA; Rao TS; Smith ND; Hager JH
    Mol Cancer Ther; 2008 May; 7(5):1054-65. PubMed ID: 18483295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
    Payne JE; Bonnefous C; Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Hoffman TZ; Rao TS; Shiau AK; Malecha JW; Noble SA; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6093-6. PubMed ID: 18954983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor, exerts antimyeloma effects by DNA damage and mitochondrial signaling.
    Feng R; Ma H; Hassig CA; Payne JE; Smith ND; Mapara MY; Hager JH; Lentzsch S
    Mol Cancer Ther; 2008 Jun; 7(6):1494-505. PubMed ID: 18566220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer.
    Kulp SK; Chen CS; Wang DS; Chen CY; Chen CS
    Clin Cancer Res; 2006 Sep; 12(17):5199-206. PubMed ID: 16951239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo.
    Fournel M; Bonfils C; Hou Y; Yan PT; Trachy-Bourget MC; Kalita A; Liu J; Lu AH; Zhou NZ; Robert MF; Gillespie J; Wang JJ; Ste-Croix H; Rahil J; Lefebvre S; Moradei O; Delorme D; Macleod AR; Besterman JM; Li Z
    Mol Cancer Ther; 2008 Apr; 7(4):759-68. PubMed ID: 18413790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models.
    Hiriyan J; Shivarudraiah P; Gavara G; Annamalai P; Natesan S; Sambasivam G; Sukumaran SK
    Anticancer Res; 2015 Jan; 35(1):229-37. PubMed ID: 25550555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
    Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
    Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Class IIb HDAC Inhibition Enhances the Inhibitory Effect of Am80, a Synthetic Retinoid, in Prostate Cancer.
    Ishigami-Yuasa M; Ekimoto H; Kagechika H
    Biol Pharm Bull; 2019; 42(3):448-452. PubMed ID: 30828077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
    Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
    Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies.
    Arts J; Angibaud P; Mariën A; Floren W; Janssens B; King P; van Dun J; Janssen L; Geerts T; Tuman RW; Johnson DL; Andries L; Jung M; Janicot M; van Emelen K
    Br J Cancer; 2007 Nov; 97(10):1344-53. PubMed ID: 18000499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer.
    Tang YA; Wen WL; Chang JW; Wei TT; Tan YH; Salunke S; Chen CT; Chen CS; Wang YC
    PLoS One; 2010 Sep; 5(9):e12417. PubMed ID: 20856855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CRA-026440: a potent, broad-spectrum, hydroxamic histone deacetylase inhibitor with antiproliferative and antiangiogenic activity in vitro and in vivo.
    Cao ZA; Bass KE; Balasubramanian S; Liu L; Schultz B; Verner E; Dai Y; Molina RA; Davis JR; Misialek S; Sendzik M; Orr CJ; Leung L; Callan O; Young P; Dalrymple SA; Buggy JJ
    Mol Cancer Ther; 2006 Jul; 5(7):1693-701. PubMed ID: 16891455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer.
    Novotny-Diermayr V; Sangthongpitag K; Hu CY; Wu X; Sausgruber N; Yeo P; Greicius G; Pettersson S; Liang AL; Loh YK; Bonday Z; Goh KC; Hentze H; Hart S; Wang H; Ethirajulu K; Wood JM
    Mol Cancer Ther; 2010 Mar; 9(3):642-52. PubMed ID: 20197387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-mercaptoketone based histone deacetylase inhibitors.
    Wash PL; Hoffman TZ; Wiley BM; Bonnefous C; Smith ND; Sertic MS; Lawrence CM; Symons KT; Nguyen PM; Lustig KD; Guo X; Annable T; Noble SA; Hager JH; Hassig CA; Malecha JW
    Bioorg Med Chem Lett; 2008 Dec; 18(24):6482-5. PubMed ID: 18954984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
    Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
    Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
    Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
    Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model.
    Miyanaga A; Gemma A; Noro R; Kataoka K; Matsuda K; Nara M; Okano T; Seike M; Yoshimura A; Kawakami A; Uesaka H; Nakae H; Kudoh S
    Mol Cancer Ther; 2008 Jul; 7(7):1923-30. PubMed ID: 18606719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitors suppress the inducibility of nuclear factor-kappaB by tumor necrosis factor-alpha receptor-1 down-regulation.
    Imre G; Gekeler V; Leja A; Beckers T; Boehm M
    Cancer Res; 2006 May; 66(10):5409-18. PubMed ID: 16707469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
    Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
    Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.